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Executive summary 
 
Does antibiotic resistance exist? 
 
Yes. It is a worsening phenomenon seen all over the world, including Australia. 
 
What are the implications of antibiotic resistance? 
 
Infection with antibiotic-resistant bacteria is associated with longer length of stay in hospitals and 
higher death rates. This amounts to significant financial costs; the European Union, for example, 
spends €1.5 billion annually on antibiotic-resistant infections. Significant indirect costs can also 
arise from antibiotic-resistant infections when they adversely affect other areas of medicine, for 
example, transplant medicine, surgery and chemotherapy. 
 
How did we get here? 
 
Antibiotic resistance has many causes but the most important ones include: excessive and 
inappropriate antibiotic use among humans and animals (including ‘over-the-counter’ antibiotic 
use), global trade, global travel, medical tourism, environmental contamination with antibiotics, and 
a decline in new antibiotic development. 
 
What can we do? 
 
Because there are multiple causes, a multi-pronged solution is required. The ‘EVADES BUGS’ 
strategy seeks to address the core problems: Education, Vaccine development, Animal health, 
Diagnostics, Environmental controls, Surveillance, Better antibiotics, Universal infection control and 
hand hygiene, Government and political will, Stewardship of antibiotics in hospitals. 
 
Many superbugs arrive here from overseas as a consequence of global trade and global travel. As 
a result, Australia must play a global role in addressing the issue as well as a local one. 
 
Implementing the EVADES BUGS strategy would require activity across portfolios (for example, 
Health, Trade, Agriculture, Environment, Tourism, Customs). Therefore, it is worth considering the 
establishment of a single coordinating body, such as an Australian Centre for Disease Control, to 
take responsibility for the strategy as part of a broader focus on monitoring and responding to 
communicable diseases. 
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Antibiotic resistance: the challenge for  
Australian health policymakers 
 
‘Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us 
 could go into hospital in 20 years for minor surgery and die because of an ordinary infection 
 that can't be treated by antibiotics.’ 
Professor Dame Sally Davies, United Kingdom Chief Medical Officer, March 2013.1 
 
The problem 
 
Bacteria have always had the ability to become resistant to antibiotics. However it wasn’t until the 
introduction of antibiotics last century that this started to have clinical implications. For example, 
the antibiotic methicillin was introduced in 1960 and it was only in 1962 that staphylococci resistant 
to methicillin were found. Erythromycin was introduced in 1950 and tetracycline-resistant strains of 
Shigella were identified by 1959. In 1972, vancomycin was introduced and vancomycin-resistant 
enterococcus was identified in 1988. Even with rapid advances in medical technology, antibiotic 
resistance remains a major problem. Linezolid and ceftaroline are two relatively new (and 
expensive) antibiotics that were introduced in 2000 and 2010 respectively: both had generated 
resistant bacteria within a year of their appearance.2 
 
Antibiotic resistance is a major health problem that can have a devastating impact on individual 
patients. The case study below in Box 1 illustrates one such devastating case where a relatively 
young, healthy man had an accident and ended up dying because he contracted an infection that 
was resistant to all antibiotics. 
 
 
 
 
 
 
 
 
 
 
 
 
Box 1. Fatal case of multi-resistant infections in a young man.3 
 
While obviously devastating for this patient and his family, this scenario also has a terrible impact 
on healthcare workers who, despite having access to expensive and extensive antibiotics, are 
helpless to intervene. 
A 40-year-old man, previously healthy, had an accident and was admitted to intensive care 
with lung bruising and fractures. It was discovered that he had a urine infection that was 
resistant to most antibiotics. He was initially treated with an extremely powerful antibiotic 
and improved. Three days later, however, he developed pneumonia, which was also 
resistant to antibiotics. Medical staff treated him with two other powerful and dangerous 
antibiotics, but his condition did not improve. Further testing revealed that he had a new 
bacterium that was resistant to all the previously used antibiotics. There was only one 
antibiotic available that could work. He was given this antibiotic but the bacterium even 
became resistant to it as well. Without any antibiotics at all to treat him, he died.  
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Unfortunately, cases such as the one outlined above are not rare. In the United States, 23,000 
deaths and over two million illnesses due to antibiotic-resistant bacteria are reported every year.2 
Similarly in Europe, rates of antibiotic resistance among an important group of bacteria (Gram-
negatives) have been steadily increasing.4 And here in Australia, there has been a rise in multi-
resistant bacteria (for example, Gram-negatives, vancomycin-resistant enterococcus (VRE), and 
community-acquired methicillin-resistant staphylococcus aureus (MRSA)).5-7 Some of the most 
common strains of multi-resistant bacteria are listed below: 
 
· MRSA (Methicillin-resistant Staphylococcus aureus or methicillin-resistant ‘golden staph’) 
· VRE (Vancomycin-resistant enterococci) 
· Clostridium difficile infection (C. diff) 
· MROs (Multiresistant Organisms) 
· Ceftriaxone-resistant gonorrhoea 
· Drug-resistant Streptococcus pneumoniae 
 
Further details about each of these bacteria are provided in Appendix A. 
 
What are the implications of antibiotic resistance? 
 
There are direct and indirect costs from multi-resistant bacteria, and both are significant. 
 
The human cost of an antibiotic-resistant infection can be death. And this is not just for isolated 
cases. In fact, people with a relatively common ailment – for example, a bloodstream infection (or 
septicaemia) – are much more likely to die from the infection if it is caused by a resistant bacterium 
than a non-resistant one (60% versus 20%).8,9  
 
In terms of financial cost, antibiotic resistance is an expensive affair. The European Union spends 
€1.5 billion on antibiotic-resistant infections each year. The costs are attributed to healthcare 
expenses and lost productivity.10 In the United States, a study recently estimated the costs 
associated with treating people with antibiotics when they had a sore throat (antibiotics do not need 
to be used in 90 per cent of cases but they were used in about 60 per cent of them). Researchers 
found that between 1997 and 2010, using antibiotics in the United States to treat sore throats cost 
about US$500 million. That was a conservative estimate, so the authors speculated that it could 
have cost up to 40 times more.11  
 
The costs associated with antibiotic resistance, however, do not only come from treating people 
unnecessarily with antibiotics. It also costs more to treat people with antibiotic-resistant infections 
than it does to treat people with non-resistant infections. Take, for example, the case of a 40 year-
old woman with a urinary tract infection. Upon discovering that she has a multi-resistant infection, 
her general practitioner sends her to the emergency department for treatment. She is not that 
 4 
 
unwell, but because there are no oral antibiotic treatment options available, she needs to be 
treated in hospital with intravenous antibiotics.  
 
In this case, the extra costs for treating this woman arise because: 
 
· more expensive antibiotics are required  
· she needs hospital treatment instead of treatment at home 
· she needs to be treated in a single room in hospital  
· extra consumables, such as gowns and gloves, are required by staff in order to prevent 
cross-infection.12,13 
 
Many other direct costs are associated with treating patients who have antibiotic-resistant 
infections. They largely arise because the patient becomes a much higher risk, particularly in areas 
of medicine where infections are common complications – surgery and chemotherapy, for 
example. When antibiotic-resistant infections take hold, treatment options can be rendered 
ineffective, and the outcomes catastrophic.  
 
What causes antibiotic resistance? 
 
A number of problems have contributed to antibiotic resistance, both in Australia and globally. They 
are outlined briefly below. 
 
Unnecessary or inappropriate antibiotic use in humans 
 
While antibiotics are a vital weapon in the war against disease, they do not need to be used all the 
time. And when required, the antibiotic with the narrowest spectrum of antibacterial activity should 
be prescribed. Unfortunately, these practices are often ignored. This happens in the hospital and 
community, resulting in excessive and unnecessary use of antibiotics to which bacteria get 
exposed. Data at both the community and hospital level show that there is a strong correlation 
between antibiotic use and antibiotic resistance.14-20 2010 data from the Organisation for Economic 
Co-operation and Development (OECD) show that Australia was one of the highest consumers of 
antibiotics, coming in eighth out of twenty nine countries. Australia used 24.1 defined daily doses 
per 1000 people per day. The OECD average was 20.5 with the biggest consumer being Greece at 
39.4 and the lowest being Chile at 9.7.21 
 
A common example of the overuse of antibiotics is in the treatment of sore throats. In 90 per cent 
of cases, sore throats are due to a virus so there is no need for antibiotics. However an American 
study recently found that in 60 per cent of cases, patients received antibiotics even though it was 
warranted in only 10 per cent of them. To compound the problem, instead of using a simple 
narrow-spectrum antibiotic like penicillin, more expensive and broader-spectrum antibiotics were 
often used.11 Australian doctors appear to be prescribing less antibiotics (just over 30%) for acute 
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upper respiratory tract infections (URTI). They are also seeing less patients with acute URTIs in 
their practice compared to just over a decade ago. While this is heartening, there is still room for 
improvement.22 
 
There are a number of reasons why antibiotics are inappropriately prescribed, and they involve 
patients, doctors and suppliers.  
 
Among doctors, there are some that continue to believe that antibiotic resistance is not a major 
problem. One Swedish study, for example, surveyed doctors about their treatment of urine 
infections, and identified two groups who said that either antibiotic resistance was not a problem at 
all, or that it was a problem, but not in their practice.23  
 
Doctors also sometimes prescribe antibiotics unnecessarily because of a perceived patient 
demand for it. This practice is particularly concerning because there is some research showing that 
doctors are not good at determining whether or not patients are expecting them to prescribe an 
antibiotic.24 Nevertheless, patients do come to the doctor with the expectation that they will receive 
antibiotics. They often believe that antibiotics will hasten their recovery or make them better. This 
may be because they were given antibiotics previously for the same condition and felt that it 
helped, or perhaps because friends or family were given antibiotics for a similar illness.25 However, 
a patient’s desire for antibiotics is a poor reason to prescribe them. Research on patients 
presenting to the doctor with an acute cough, for example, has shown that the patients that come 
with expectations or hopes for antibiotics are often not the ones who would benefit from them.24  
 
A survey of 1,013 Australians by the National Prescribing Service’s MedicineWise showed that four 
in five expect a prescription from their general practitioner for an ear, nose, throat or chest 
infection. Over half (51%) said that they would ask their doctor for one. Parents would be twice as 
likely to ask for antibiotics to treat their child’s cold or cough than their own (14% vs 6%), with 
fathers more likely to ask than mothers (22% vs 9%). The survey also identified a number of 
misconceptions related to antibiotics. For example, only half of respondents knew that bacteria are 
becoming resistant to antibiotics, only 40 per cent knew that antibiotics should not be taken for 
viruses and 40 per cent did not know that taking antibiotics when they’re not needed contributes to 
antibiotic resistance. More than 50 per cent were not aware that resistance increases when an 
antibiotic course is not completed as directed. Young people were less knowledgeable on the 
matter.26  
 
In many parts of the world, antibiotics are available over-the-counter or without a prescription. The 
rates of non-prescription use of antibiotics by the general population vary: three per cent in the UK, 
Netherlands and Denmark, 18 per cent in India, 36 per cent in China, 46 per cent in Brazil, 62 per 
cent in Vietnam and 100 per cent in Sudan and Nigeria. This practice means that often the wrong 
antibiotic is used, the wrong dose is taken, or the course of antibiotics is too short. All of these 
problems contribute to antibiotic resistance, so it should come as no surprise that antibiotic 
resistance is an issue in regions with high non-prescription antibiotic use.27 
 6 
 
Antibiotic use in animals 
 
Antibiotic use in animals is very common; they are used to promote growth, to prevent illness and 
treat it. Antibiotic use in animals is far greater than it is in humans. In the United States, for 
example, 80 per cent of the total volume of antibiotics sold in 2011 was for use in meat and poultry 
production.28 
 
As with humans, when animals take antibiotics, it causes resistant bacteria to appear. This 
becomes a problem for humans in a number of ways. Most obviously, people consume meat that 
contains resistant bacteria. Resistant bacteria can also spread via animal waste into the water 
supply and fertilisers, and some studies have found resistant bacteria in farm workers, food animal 
transport trucks and non-domesticated animals.28  
 
When resistant bacteria grow in animals, there is a flow-on effect in humans because the 
antibiotics used to treat animals come from the same families as those used to treat humans. In 
other words, cross-resistance can develop. For example, in countries such as the United States, 
most antibiotic-resistant E. coli in humans is derived from food animals.29 This is of great 
significance considering that E. coli is the most common cause in humans of urine infections and 
one of the leading causes of bloodstream infections. 
 
Global travel and medical tourism 
 
Every year, around two billion people travel across large distances, with about one billion travelling 
internationally.30 All this global travel helps spread antibiotic-resistant bacteria.  
 
Because some nations have very high rates of antibiotic resistance, no country can develop an 
effective strategy for controlling antibiotic-resistant bacteria by acting alone.3,31-33 The hard work 
done by a country controlling antibiotic-resistant bacteria within its own borders can easily be 
undone when overseas travellers return with undeclared superbugs in their bowels. Numerous 
international studies show this.34-37 One Australian study, for example, looked at the number of 
travellers leaving Australia with antibiotic-resistant E. coli and compared it to rates among those 
returning to Australia. They found that travellers were six times more likely to be carrying antibiotic-
resistant E. coli when returning to Australia, especially from Asia. While most travellers got rid of 
the antibiotic-resistant E. coli six months after returning to Australia, 18 per cent still had the 
bacterium, heightening the risk that it will move from people into our local environment and become 
established here.37  
 
‘Medical tourism’, where people go overseas for a medical procedure, is also becoming 
increasingly common. People go overseas seeking treatment for a variety of reasons (for example, 
treatment costs might be lower overseas or they think they will get better care), and for a variety of 
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procedures (for example, cosmetic surgery, orthopaedic surgery, transplant surgery or dental 
procedures). They are travelling from developing countries to developed ones and vice versa. 
 
Australian media have reported that medical tourism is on the rise here with Australians travelling 
overseas for a variety of procedures.38 There are companies in Australia that arrange medical 
procedures overseas somewhat like a travel agency. Even a local health fund is participating.39,40  
 
There are two reasons why medical tourism heightens the risk of picking up antibiotic-resistant 
bacteria. First, some of the popular destinations for medical tourism have higher rates of antibiotic-
resistant bacteria than Australia.32,38 And second, unlike other tourists, medical tourists will be 
exposed to healthcare facilities in these countries where there are more antibiotic-resistant 
bacteria. Cases of antibiotic-resistant infections associated with medical tourism have already been 
reported in the scientific literature.41 
 
Lack of new antibiotics 
 
The emergence of bacteria resistant to antibiotics would be much less of a problem if there were 
plenty of alternative antibiotics available to treat people. Unfortunately, the development of new 
antibiotics has also slowed down. American data show an almost 20-fold drop in submissions for 
new antibiotics between 1980-84 and 2010-12.2 The lack of new antibiotics being developed is 
especially problematic in some areas. For example, in the case of a common gram-negative 
bacterium (pseudomonas), only one effective oral antibiotic has been available in the last 20 years.  
 
Environmental contamination 
 
Antibiotic-resistant bacteria are contaminating the environment; they have been found in 
waterways and sewage outlets, even in Australia. One of the reasons this problem has emerged is 
that antibiotic-resistant bacteria are sometimes excreted directly into the environment, for example 
in hospital wastewater.42 Another is that antibiotics in the water coexist with antibiotic-sensitive 
bacteria, which can cause them to become resistant. One of the main problems with excreting 
antibiotics into the environment is that they can survive for long periods of time; some have been 
shown to persist in the environment for over a year.43  
 
What can be done to prevent antibiotic resistance? 
 
The term “EVADES BUGS” was developed for the purposes of this report. Its components are 
recognized in both international literature and practice.2,10,44 
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The EVADES BUGS Strategy: 
 
• Education 
• Vaccine development 
• Animal health 
• Diagnostics 
• Environmental controls 
• Surveillance 
 
• Better antibiotics 
• Universal infection control and hand hygiene 
• Government and political will 
• Stewardship of antibiotics in hospitals 
 
Education 
 
Most antibiotic consumption occurs in the community, so it is vital to continue to educate doctors, 
nurse practitioners and patients about the appropriate use of antibiotics. Many programs have 
been developed to reach these key stakeholders. In Australia, the National Prescribing Service’s 
MedicineWise website has an e-learning tool to promote antibiotic awareness.45  
 
Australia is also part of a global initiative held every November called ‘Antibiotic Awareness Week’ 
that highlights issues related to antibiotic resistance and the responsible use of antibiotics.46  
 
A number of other educational tools are also available internationally. The United Kingdom, for 
instance, has developed a tool for patients and healthcare workers called TARGET (Treat 
Antibiotics Responsibly, Guidance and Education Tool). It is promoted by the Royal College of 
General Practitioners on its website.47 In the United States, the Centers for Disease Control and 
Prevention (CDC) has its own ‘Get Smart’ program aimed at educating people about appropriate 
antibiotic use.2 Studies examining the impact of these education tools have shown that they lead to 
improvements in antibiotic prescribing.48,49 However the CDC points out that while these programs 
might be effective, they are not widely used.2 
 
Vaccine development 
 
Immunizing the population against infection from antibiotic-resistant bacteria is one of the best 
ways of preventing it. This strategy has been used quite successfully against some antibiotic-
resistant bacteria like Streptococcus pneumoniae (the most common cause of pneumonia and 
middle ear infections in children), but less so in others (for example, golden staph).50,51 Ongoing 
development of vaccines against antibiotic-resistant bacteria is also recommended by authorities in 
the United Kingdom.10 
 9 
 
Animal health 
 
The World Health Organization’s Advisory Group on Integrated Surveillance of Antibiotic 
Resistance published a document on the critically important antibiotics used in both humans and 
animals. The aim of the document is to provide a reference to develop risk management strategies 
in this area. Key uses of the document include:52  
 
• Prioritizing for most urgent development of risk management strategies those antibiotics 
characterized as critically important in order to preserve their effectiveness in human medicine. 
• Ensuring that critically important antibiotics are included in antibiotic susceptibility monitoring 
programs. 
• Refining and prioritizing risk profile and hazard analysis activities for interventions by species or 
by region. 
• Developing risk management options such as restricted use, labelling, limiting or prohibiting 
extra-label use, and making antibiotics available by prescription only. 
• For the development of prudent use and treatment guidelines in humans and animals. 
• To direct special research projects to address prevalence data gaps on existing or potential 
future critically important antibiotics. 
 
Another worldwide innovation has been ‘One Health’, which is a global network of veterinarians 
and healthcare workers for humans who are working closer together in recognition of the link 
between animal and human health.53 
 
In Australia, the Australian Commission on Safety and Quality in Health Care has examined the 
issue of antibiotic use in the animal industry. It found that the Department of Agriculture, Fisheries 
and Forestry monitors the scientific literature and is increasingly aware of the complexities between 
animal and human health. It also noted that Meat and Livestock Australia is funding an 
investigation into antibiotic-resistant bacteria in red meat, which is due for completion in 2014. The 
Australian Veterinary Association is also promoting the judicious use of antibiotics in animals 
through its guidelines for prescribing, authorising and dispensing veterinary medicines.54,55 
 
Like global travel, global trade means that animal products from overseas come into Australia, and 
antibiotic use may not be as strictly regulated in some of the countries they are coming from. For 
example, last year, consignments of fish from Vietnam were found to contain an antibiotic that is 
banned in Australia.56 Therefore, Australia has a vested interest in ensuring that other nations are 
successful when it comes to antibiotic regulation in their food and crop industry. 
 
Diagnostics 
 
Developing more rapid and accurate diagnostic tests will help health professionals to differentiate 
between viral infections that do not need antibiotics, and bacterial infections that might. Such tests 
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must also be able to quickly determine if any bacteria present are antibiotic-resistant or not. This is 
important at a community level because there are some infections (for example, ceftriaxone-
resistant gonorrhoea) where patients can be given an ineffective antibiotic and think that they are 
cured, which allows them to unwittingly spread the superbug to other people.  
 
At a hospital level, the ability to accurately diagnose bacterial infections and detect antibiotic-
resistant bacteria would have enormous benefits. It would allow staff to quickly determine whether 
a patient needed to be isolated to prevent the infections spreading. It would also mean that the 
best antibiotic could be started as soon as possible.10 
 
Environmental controls 
 
A multidisciplinary approach involving hospitals, pharmaceutical companies and sewage plants is 
needed to prevent the spread of antibiotic-resistant bacteria in the environment. Whether this has 
happened yet or not is unclear. Even individuals can make a difference by not disposing of drugs 
“down the drain”.43 
 
Surveillance 
 
Routinely collected surveillance data can be used to highlight problem areas that need urgent 
action. In Australia, the data on golden staph bloodstream infections on the MyHospitals website is 
possibly one example of how the inclusion these data may stimulate improvements in infection 
control overtime.57 The number of golden staph bloodstream infections in a hospital is a surrogate 
marker for infection control problems. When high infection rates are publicly reported, it should 
prompt hospitals to review and improve their infection control practices.  
 
Many countries have surveillance programs in place for antibiotic-resistant bacteria – in Australia, 
there is the Australian Group on Antimicrobial Resistance (AGAR), and in Europe there is EARS-
Net .58,59 AGAR is a non-governmental organisation made up of laboratory-based doctors from 
around Australia that periodically publishes data on the number of antibiotic-resistant bacterial 
infections. While it serves a valuable role, it is not able to be a single surveillance centre capable of 
capturing data on all community and hospital cases of antibiotic-resistant bacterial infections. As 
the American Centers for Disease Control and Prevention has pointed out, the lack of routine 
surveillance of antibiotic resistance internationally is also a major problem.2  
 
Surveillance should not be exclusive to humans. Antibiotic resistance patterns in agriculture and 
aquaculture should also be monitored because of their implications for human health. 
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Better antibiotics 
 
Pharmaceutical companies must be encouraged to develop new antibiotics, especially to treat 
Gram-negative bacteria. Potential obstacles to this include the perception that development in this 
area has a poor return on investment compared with drugs for cholesterol or hypertension. For 
example, a new antibiotic, at discovery, is worth “minus” $50 million to a pharmaceutical company. 
This is in comparison to discovery of a drug for musculoskeletal pain, which is worth “plus” $1 
billion.60 Other obstacles for companies to develop new antibiotics are uncertainty about the 
regulatory environment for developing new antibiotics and the cost and complexity of dealing with 
the regulatory process.10  
 
In the United States, one strategy to deal with this has been the passage of the GAIN Act - 
“Generating Antibiotic Incentives Now”. It uses a number of mechanisms, including prolonged 
exclusivity, to make the development of antibiotics more attractive to a pharmaceutical company. In 
concert with this, the Infectious Diseases Society of America has proposed the Special Populations 
Limited Medical Use scheme which seeks to fast-track the approval of newly developed antibiotics 
by minimizing their regulatory processes.60 
  
Universal infection control and hand hygiene 
 
As well as preventing antibiotic-resistant bacteria from developing, measures must be taken to stop 
infections from spreading. This is crucial in hospitals where spreading antibiotic-resistant bacterial 
infections to vulnerable patients can be catastrophic. One way of doing this is to have appropriately 
skilled and resourced infection control units in hospitals.  
 
Although there are many facets to infection control (for example, isolation in single rooms, 
education, and wearing personal protective equipment), the importance of hand hygiene in clinical 
settings cannot be overstated. The World Health Organization is taking a leading role in promoting 
hand hygiene. Locally, Hand Hygiene Australia is promoting the National Hand Hygiene Initiative, 
which is based on the World Health Organization’s hand hygiene advice. The initiative promotes 
cleaning hands with soap and water or an alcohol-based hand rub to reduce bacteria.61 Regular 
hand hygiene audits are conducted in hospitals around Australia, and the results are published on 
the MyHospitals website.57  
Government and political will 
 
Because there are many causes of antibiotic resistance, tackling it effectively requires strong 
leadership at a senior government level. It needs coordinated action across portfolio areas, 
including health, agriculture, environment, customs, tourism, science, immigration, and trade. 
There are positive signs internationally that the necessary steps are being taken. 
 
Over a decade ago, the World Health Organization issued its strategy to combat antibiotic 
resistance.62  
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In the United States, an interagency task force on antibiotic resistance has been established with 
members from 12 federal agencies, including Defence, Veterans Affairs, and Agriculture.63  
 
In India, a multi-pronged approach to addressing antibiotic resistance has been put in place – the 
Chennai Declaration. It was born out of the negative press generated when a very resistant 
superbug, NDM-1, was discovered in the New Delhi water supply.64 The Chennai Declaration lists 
goals and sets out one, two and five-year targets for achieving them, and has since been endorsed 
by respected international organisations.65 
 
In the United Kingdom, the Chief Medical Officer recently recommended adding antibiotic 
resistance to the National Risk Register of Civil Emergencies alongside other civil threats such as 
pandemic influenza, terrorism and coastal flooding.10,66 
 
And most recently, in June 2013, the G8 joint Science Ministers discussed antibiotic resistance, 
naming it as one of the leading health security challenges of this century.67 
 
Stewardship of antibiotics in hospitals 
 
Antimicrobial stewardship (AMS) programs are a systematic way of rationalising antibiotic use in 
healthcare institutions. Studies have shown that AMS programs improve antibiotic and patient 
outcomes while reducing adverse events and costs.68-71  
 
Because patients in Australian hospitals are prescribed more antibiotics than they are in Europe, 
and up to half of antibiotic regimens prescribed are regarded as inappropriate, the Australian 
Commission for Safety and Quality in Health Care has made it mandatory for all hospitals to have 
an AMS program.71 The objectives of the program are to: 
 
• Provide clinicians prescribing antibiotics with access to current, endorsed therapeutic guidelines 
on antibiotic usage  
• Undertake monitoring of antibiotic usage and resistance 
• Take action to improve the effectiveness of antibiotic stewardship.72 
 
Accreditation of such programs in Australian hospitals began in January 2013. An AMS program 
often consists of a multidisciplinary team of pharmacists, infectious diseases physicians and 
clinical microbiologists. A recent analysis of AMS programs in public and private health facilities in 
regional and metropolitan Victoria was performed. The investigators found that AMS programs in 
metropolitan public hospitals were more advanced than their counterparts in private hospitals or 
regional public hospitals. In particular, these latter groups fell behind in establishing formulary 
restriction and approval systems. But even the public hospitals fell short in having a dedicated 
antibiotic management team, performing regular audits and giving feedback to prescribers. Three 
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barriers to implementing a better AMS program that they identified included a lack of resources, 
lack of leadership and a reluctance of doctors to change their prescribing habits.73 
 
Conclusion 
 
Antibiotic resistance is a global concern that has already led to people dying from untreatable 
infections, bringing back memories of the pre-antibiotic era. The problem is caused by a variety of 
factors encompassing both animal and human health and affects many different bacteria.  
 
There has been a global push to address antibiotic resistance, but only some countries have 
classified it as a priority issue. Australia needs to be part of global efforts to tackle antibiotic 
resistance, if for no reason other than global travel and trade mean superbugs will be introduced 
here from overseas.  
 
Because the origins of antibiotic resistance are complex, so is the solution. Australia should adopt 
the EVADES BUGS strategy, which seeks to address the key drivers of resistance. Coordinated 
cross-government action will be required to ensure the effectiveness of the EVADES BUGS 
strategy. The best way to achieve this is to coordinate action under a single body, capable of 
monitoring real-time progress. To this end, Australia should consider establishing an Australian 
Centre for Disease Control that is dedicated to monitoring communicable diseases.  
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Appendix A – Common types of antibiotic-resistant bacteria  
 
Some of the most problematic antibiotic-resistant bacteria are listed here. Of those discussed 
below, the American Centers for Disease Control and Prevention this year classified three of them 
as belonging to the most serious threat level: Clostridium difficile, Carbapenem-resistant 
Enterobacteriaceae and Drug-resistant Gonorrhoea.  
 
MRSA (Methicillin-resistant Staphylococcus aureus or methicillin-resistant “golden staph”) 
 
There are two types of MRSA: one that is strongly associated with hospitals and the other that is 
more common in the community. MRSA lives on the skin and in the nose. The community form of 
MRSA is well known for causing aggressive pneumonia in children and serious skin infections that 
often need a combination of surgical drainage and antibiotics. On the other hand, the hospital 
strain of MRSA is harmless if it is just colonising the skin or the nose. But, if it gets inside a person, 
then it is extremely dangerous. And hospitals are full of vulnerable patients with ‘passageways’ 
from the skin to their insides e.g. intravenous cannulas and surgical wound infections. In Australia, 
even with the best medical care, the overall death rate from MRSA in the bloodstream is more than 
20 per cent.  
 
VRE (Vancomycin-resistant enterococci) 
 
Enterococcus is a normal member of the bacteria in our bowel. VRE occurs when it becomes 
resistant to an important intravenous antibiotic called vancomycin. VRE is a growing problem in 
Australia that is associated with antibiotic use and being in regular contact with the healthcare 
system due to chronic illnesses e.g. dialysis for kidney failure. When infection due to VRE occurs, 
expensive antibiotics with serious side effects have to be used. 
 
Clostridium difficile infection (“C. diff”) 
 
Whenever an antibiotic is taken (e.g. for a sore throat), it wipes out billions of bacteria in the 
bowels, leaving only more resistant ones behind. One of these resistant bacteria is C.diff. When C. 
diff is left unchecked, it can cause diarrhoea, dehydration, and may require surgical treatment. 
More than 15 per cent of people may die. In 2012 in the United States, there were 250,000 cases 
of C. diff cases with 14,000 deaths and one billion dollars excess in costs. Not surprisingly, the 
Americans have classified C. diff within its most serious threat level.  
 
MROs (Multiresistant Organisms) 
 
Under the banner of MROs comes a large group of superbugs such as CRAB, ESBL, ESCAPPM, 
NDM-1, KPC and CRE, multidrug-resistant Pseudomonas, to name but a few. Foodborne threats 
such as drug-resistant Salmonella and drug-resistant Campylobacter are no less important. Their 
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evolution has been complex. CRE (or Carbapenem-resistant Enterobacteriaceae) cause 9000 
cases and 600 deaths every year in the United States. The Centers for Disease Control and 
Prevention has classified it amongst its highest threat group.  
 
Ceftriaxone-resistant gonorrhoea 
 
In Australia last year, gonorrhoea was one of the leading notifiable diseases. If untreated, 
gonorrhoea can cause a variety of problems, including urethritis, infertility, and death. Currently, 
there are limited antibiotics with which to treat gonorrhoea. The situation worsened when Japanese 
health authorities announced the first case of ceftriaxone-resistant gonorrhoea in 2011. If this drug-
resistant strain of gonorrhoea were to spread, the results would be devastating. And given the 
prevalence of gonorrhoea and the ease with which sexually-active individuals can travel the world, 
it is no surprise that the American Centers for Disease Control and Prevention has included drug-
resistant gonorrhoea as one of three bacteria in its highest threat level of action. 
 
Drug-resistant Streptococcus pneumoniae 
 
Worldwide, this bacterium is the commonest cause of community-acquired pneumonia and 
bacterial middle ear infections. Growing resistance to penicillin and a related group of antibiotics 
called cephalosporins is of great concern. However, this is one area where vaccine development 
has been very helpful.  
 
 
 
 
 
 
 
 22 
 
References for Appendix A 
 
1.  Centers from Disease Control and Prevention. Antibiotic Resistance Threats in the United 
States, 2013. Centers for Disease Control and Prevention [Internet]. 2013 Sept 16 [cited 2013 
Oct 21]. Available from http://www.cdc.gov/drugresistance/threat-report-2013/.  
2. Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteraemia: a major 
cause of mortality in Australia and New Zealand. Med J Aust. 2009;191(7):368-73. 
3. Pearson J, Christiansen K, Turnidge J, Bell J, Gottlieb T, George N. Vancomycin resistant 
enterococci in Australia: results of the AGAR surveys 1995 to 2010. Australian Group for 
Antimicrobial Resistance [Internet]. 2011 [cited 2013 Oct 31]. Available from 
http://www.agargroup.org/files/VRE%20in%20Australia.pdf. 
4.  Warny M, Pepin J, Fang A, Killgore G, et al. Toxin production by an emerging strain of 
Clostridium difficile associated with outbreaks of severe disease in North America and Europe. 
Lancet. 2005;366(9491):1079-84. 
5. National Notifiable Diseases Surveillance System. Number of notifications of Gonococcal 
infection, Australia, in the period of 1991 to 2012 and year-to-date notifications for 2013. 
Department of Health and Ageing [Internet]. 2013 Nov 3 [cited 2013 Nov 3]. Available from 
http://www9.health.gov.au/cda/source/rpt_3.cfm 
6.  Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. 
Emerg Infect Dis. 2011;17(1):148. 
 
 
